UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12970) 12970
Book Chapter (135) 135
Magazine Article (52) 52
Newsletter (33) 33
Dissertation (6) 6
Publication (4) 4
Reference (4) 4
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9115) 9115
science & technology (8914) 8914
life sciences & biomedicine (8738) 8738
male (7099) 7099
angiotensin-converting enzyme inhibitors - therapeutic use (5359) 5359
female (5024) 5024
animals (4019) 4019
middle aged (3695) 3695
angiotensin-converting enzyme inhibitors - administration & dosage (3694) 3694
angiotensin-converting enzyme inhibitors - pharmacology (3215) 3215
cardiovascular system & cardiology (3192) 3192
aged (3104) 3104
hypertension - drug therapy (2968) 2968
blood pressure - drug effects (2634) 2634
adult (2425) 2425
rats (2324) 2324
hypertension (2122) 2122
pharmacology & pharmacy (2076) 2076
cardiac & cardiovascular systems (2010) 2010
angiotensin (1817) 1817
drug therapy, combination (1743) 1743
abridged index medicus (1647) 1647
treatment outcome (1634) 1634
angiotensin-converting enzyme inhibitors (1593) 1593
angiotensin-converting enzyme inhibitors - adverse effects (1587) 1587
heart failure - drug therapy (1494) 1494
peripheral vascular disease (1462) 1462
ace inhibitors (1420) 1420
antihypertensive agents - therapeutic use (1413) 1413
heart failure (1253) 1253
enzymes (1249) 1249
renin-angiotensin system - drug effects (1235) 1235
hypertension - physiopathology (1203) 1203
risk factors (1199) 1199
blood pressure (1158) 1158
time factors (1136) 1136
antihypertensive agents - administration & dosage (1116) 1116
dose-response relationship, drug (1113) 1113
drug therapy (1058) 1058
adrenergic beta-antagonists - therapeutic use (1000) 1000
general & internal medicine (997) 997
double-blind method (950) 950
medicine, general & internal (930) 930
captopril - pharmacology (854) 854
aged, 80 and over (798) 798
urology & nephrology (787) 787
angiotensin converting enzyme (777) 777
medicine & public health (770) 770
research (727) 727
care and treatment (712) 712
angiotensin receptor antagonists (688) 688
antihypertensive agents - pharmacology (683) 683
renin-angiotensin system (659) 659
calcium channel blockers - therapeutic use (642) 642
captopril (641) 641
hypertension - complications (636) 636
follow-up studies (634) 634
angiotensin ii (630) 630
enzyme inhibitors (620) 620
retrospective studies (613) 613
angiotensin ii type 1 receptor blockers - therapeutic use (609) 609
diuretics - therapeutic use (606) 606
health aspects (602) 602
peptidyl-dipeptidase a - metabolism (602) 602
administration, oral (600) 600
heart failure - physiopathology (599) 599
hemodynamics - drug effects (599) 599
rats, sprague-dawley (598) 598
physiology (597) 597
enalapril - administration & dosage (596) 596
diabetes (590) 590
enalapril - therapeutic use (590) 590
mortality (589) 589
rats, wistar (585) 585
cardiology (584) 584
prospective studies (582) 582
rats, inbred shr (576) 576
analysis (573) 573
renin - blood (570) 570
enalapril - pharmacology (565) 565
randomized controlled trials as topic (565) 565
heart rate - drug effects (561) 561
dosage and administration (552) 552
kidney - drug effects (542) 542
captopril - therapeutic use (537) 537
captopril - administration & dosage (529) 529
enalapril (526) 526
physiological aspects (513) 513
renin-angiotensin system - physiology (511) 511
clinical trials as topic (510) 510
angiotensin-converting enzyme inhibitor (503) 503
cardiovascular disease (503) 503
adolescent (494) 494
angiotensin-converting enzyme (489) 489
drug administration schedule (487) 487
disease models, animal (483) 483
myocardial infarction - drug therapy (481) 481
internal medicine (478) 478
adrenergic beta-antagonists - administration & dosage (466) 466
angiotensin receptor antagonists - therapeutic use (462) 462
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12360) 12360
German (260) 260
Japanese (244) 244
Russian (218) 218
French (140) 140
Spanish (70) 70
Italian (56) 56
Polish (46) 46
Portuguese (38) 38
Danish (28) 28
Chinese (27) 27
Hungarian (25) 25
Swedish (23) 23
Norwegian (22) 22
Czech (18) 18
Ukrainian (9) 9
Dutch (8) 8
Lithuanian (7) 7
Finnish (6) 6
Turkish (6) 6
Hebrew (5) 5
Korean (5) 5
Romanian (5) 5
Serbian (4) 4
Croatian (3) 3
Bosnian (2) 2
Slovak (2) 2
Bulgarian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drug safety, ISSN 0114-5916, 3/2017, Volume 40, Issue 3, pp. 249 - 255
Controversy exists about an association between angiotensin-converting-enzyme inhibitors (ACEIs... 
Medicine & Public Health | Drug Safety and Pharmacovigilance | Pharmacology/Toxicology | Pharmacology & Pharmacy | Public, Environmental & Occupational Health | Toxicology | Life Sciences & Biomedicine | Science & Technology | Melanoma - epidemiology | Skin Neoplasms - pathology | Melanoma - etiology | Carcinoma, Squamous Cell - epidemiology | Humans | Middle Aged | Logistic Models | Male | Carcinoma, Basal Cell - epidemiology | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Skin Neoplasms - epidemiology | Carcinoma, Squamous Cell - etiology | Thiazides - administration & dosage | Thiazides - adverse effects | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Carcinoma, Basal Cell - etiology | Aged, 80 and over | Female | Aged | Skin Neoplasms - etiology | Electronic Health Records | Angiotensin Receptor Antagonists - administration & dosage | Angiotensin Receptor Antagonists - adverse effects | Cohort Studies | Usage | Dosage and administration | Drug therapy | Thiazides | Risk factors | Skin cancer | Health care | Drugs | Transplants & implants | Cancer therapies | Electronic medical records | Confidence intervals | Enzyme inhibitors | Peptidyl-dipeptidase A | Population | Enzymes | Squamous cell carcinoma | Comorbidity | Review boards | Melanoma | Health risks | Data warehouses | Exposure | Regression analysis | Data warehousing | Patients | Disease prevention | Studies | Inhibitors | Converting | Angiotensin | Skin | Health risk assessment | Electronic health records | Cancer
Journal Article
Journal Article
Journal Article
Archives of Dermatological Research, ISSN 0340-3696, 1/2009, Volume 301, Issue 1, pp. 99 - 105
Drug-induced lupus erythematosus (DILE) is defined as a lupus-like syndrome temporally related to continuous drug exposure which resolves after discontinuation... 
Drug-induced lupus erythematosus | Antinuclear antibodies (ANA) | Medicine & Public Health | Dermatology | Anti-TNFα-induced lupus | Anti-histone antibodies | Subacute cutaneous drug-induced lupus (SCLE) | Drug reactions | Life Sciences & Biomedicine | Science & Technology | Antifungal Agents - adverse effects | Antitubercular Agents - adverse effects | Naphthalenes - adverse effects | Antibodies - metabolism | Calcium Channel Blockers - adverse effects | Serositis | Exanthema | Humans | Isoniazid - adverse effects | Interferons - adverse effects | Antihypertensive Agents - administration & dosage | Sodium Chloride Symporter Inhibitors - adverse effects | Arthritis | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Lupus Erythematosus, Systemic - immunology | Sodium Chloride Symporter Inhibitors - administration & dosage | Tumor Necrosis Factor-alpha - immunology | Antibodies - immunology | Lupus Erythematosus, Cutaneous - chemically induced | Procainamide - administration & dosage | Lupus Erythematosus, Cutaneous - immunology | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Anti-Arrhythmia Agents - administration & dosage | Procainamide - adverse effects | Antihypertensive Agents - adverse effects | Hydralazine - adverse effects | Isoniazid - administration & dosage | Lupus Erythematosus, Systemic - diagnosis | Interferons - administration & dosage | Hydralazine - administration & dosage | Animals | Anti-Arrhythmia Agents - adverse effects | Naphthalenes - administration & dosage | Calcium Channel Blockers - administration & dosage | Antitubercular Agents - administration & dosage | Lupus Erythematosus, Systemic - chemically induced | Antifungal Agents - administration & dosage | Lupus Erythematosus, Cutaneous - diagnosis | Lupus | Antigen-antibody reactions | Enzymes | Antigens | Biological products | Antibodies | Viral antibodies | Enzyme inhibitors | Systemic lupus erythematosus | Fluocinolone acetonide | Calcium channel blockers | Diuretics | Kidney diseases | Hydralazine | Index Medicus
Journal Article
Pharmaceutical research, ISSN 0724-8741, 6/2015, Volume 32, Issue 6, pp. 1931 - 1946
Journal Article
The New England journal of medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ACTIVE CONTROLLED-TRIALS | HIGH-RISK PATIENTS | TICLOPIDINE | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ARTERIAL ORIGIN ESPRIT | CEREBRAL-ISCHEMIA | UMCG Approved | NON-INFERIORITY TRIALS | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 11/2010, Volume 56, Issue 21, pp. 1701 - 1708
Journal Article